CHPA Self-Care Leadership Summit

From Nicholas Hall’s Regional VP, North America, Liz Cummings

USA: “If there was ever any doubt, the world has learned what we knew all along – that consumer healthcare is absolutely essential to public health and that good healthcare starts with good self-care,” observed Consumer Healthcare Products Association President & CEO Scott Melville during his keynote at the CHPA annual Self-Care Leadership Summit last week.

Two areas of self-care – dietary supplements and diagnostics – were especially important to consumers during the pandemic, he noted, and CHPA’s membership expansion into those categories positions the association well to support the full scope of the industry in the future. One example is the data-driven Dietary Supplement Index (USA), which identifies supplements sales by region and provides a tool for the industry to educate healthcare providers and insurers to make the case for nutrition as essential to healthcare.  

During the meeting, the CHPA awarded its Ivan D Combe Lifetime Achievement Award to longtime industry leader – and former Chair – Gary Downing. Praised by many former employees at the event for his leadership, Downing has spent his career growing CHC companies, with a resume that includes sales and management at the Richards-Vicks Company. He later co-founded MedTech Labs, which eventually sold for a 400% rate of return, joined the Lansinoh Laboratories Board of Directors and became CEO of Insight Pharmaceuticals, then Clarion Brands, which was recently sold to Bridges Consumer Healthcare.

The audience also appreciated with standing ovations the 40-year CHPA career of Phyllis Taylor, Sr Director of Membership and Sponsorship, when her retirement was announced by Melville. We at the Nicholas Hall Group of Companies send her our very best wishes for a happy next chapter with her family.

The CHPA meeting will be reviewed in detail in the forthcoming March / April issue of CHC Insight North America. To review the latest trends and developments across the region, please contact melissa.lee@NicholasHall.com to find out more, or to receive a sample copy of a recent issue.

Two Rx-to-OTC allergy switches approved by FDA

In a clear sign of a more favourable attitude to Rx-to-OTC switch, the US FDA last week approved two new allergy products for non-prescription use.

Lastacaft alcaftadine ophthalmic 0.25% solution (Allergan / AbbVie) is now available without a prescription online and in retail stores for individuals aged 2+ years with ocular allergies. As demonstrated in clinical studies, one drop works in as little as three minutes to provide relief from itchy eyes for up to 16 hours. Following the recent FDA Rx-to-OTC switch approval, the original patented prescription-strength formulation of Lastacaft is available in a 5ml multidose bottle containing a 60-day supply, as well as a twin pack with two 5ml multidose bottles.

Perrigo also received final approval last week from the FDA for the OTC use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg). This marks the first branded Rx-to-OTC switch for the company, which expects to begin offering the nasal spray later this year. Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under licence.

Nicholas Hall’s Touchpoints: This development will no doubt lead to an increase in switch activity after House and Senate committee members cited concerns that “very few products in recent years have switched from prescription drugs to nonprescription drugs” and pointed out that the FDA is expected to “meet the goals of the Fall 2021 Unified Agenda and publish and subsequently finalise the proposed rule titled Nonprescription Drug Product with an Additional Condition for Nonprescription Use.”

The appropriations committees are also: “Concerned about dietary supplement products that are adulterated or misbranded, in particular with imported products. The agreement provides an increase of US$2mn in the FDA’s budget [US$6.1bn in total] to be used for inspections, as well as enforcement of the Dietary Supplement Health & Education Act of 1994”. My sense is that in the biggest market for both switch and dietary supplements, we could see a correction in the prevailing trend from treatment to prevention.

Take a look at the latest CHC innovations in our forthcoming 2022 edition of Innovation in CHC from CHC New Products Tracker. This report offers a look at Rx-to-OTC switch activity, as well as innovation by region, marketer and 20 individual countries. To pre-order your copy and save up to £1,350 with the pre-publication discount, or for further information on this report, please contact melissa.lee@NicholasHall.com.

Poland approves world-first OTC switch of tadalafil

We continue with the theme of Rx-to-OTC switch this week with news from Poland, where the Office for Registration of Medicinal Products, Medical Devices & Biocidal Products (URPL) has approved Adamed’s Tadalafil MaxOn ED treatment (tadalafil 10mg; film-coated tablets; 2- and 4-count SKUs) as an OTC medicine, effective 1st February 2022. This will join Adamed’s sildenafil options MaxOn Active (25mg) and MaxOn Forte (50mg), which launched in May 2016 and April 2020, respectively. Tadalafil is claimed to get to work within 30 minutes for up to 36 hours, vs claims for sildenafil that it works within 30-60 minutes for up to five hours.

Poland was again one of the most active Rx-to-OTC switch markets in 2021, with only China ahead of it last year in terms of number of launched products reclassified from prescription to OTC status. Three of the six products launched post-switch in Poland in 2021 were erectile dysfunction treatments, including Hasco-Lek’s Mensil Max, Aflofarm’s Inventum Max and Polpharma’s Maxigra Max (all sildenafil 50mg). In addition, there were two digestive health switches – Teva’s antidiarrhoeal Gastrolit and Polpharma’s antacid Famotydyna Ranigast – and Polpharma’s cold sore treatment Heviran Comfort Max.

Source: Nicholas Hall’s CHC New Products Tracker

Nicholas Hall’s Touchpoints: Last week our lead story was the likely switch of HRT in the UK, which we singled out as a pioneer. The latest news this week is from Poland, another switch centre of excellence and where the ED treatment tadalafil will be available in a non-prescription version for the first time anywhere in the world. Tadalafil was launched as a prescription medicine under the trademark Cialis, and Sanofi later acquired the CHC rights from Lilly, but the switch application in the USA has been held up for many years by the FDA.

My colleague Maryna Marriott of the CHC Insight Europe team tells me: “Poland continues to lead the way in switch innovation. The tadalafil approval follows a number of sildenafil 25mg and 50mg switches, with the Polish ED category totalling US$27.7mn in MAT Q3 2021, according to DB6, an increase of 28.5% vs the year-ago period. Men’s health clearly remains high on the consumer health agenda, and it seems likely a number of other tadalafil switches will follow in Poland.”

Switch is an expensive process in the USA, which is why it is subdued there at present. On the other hand, there has been renewed switch activity in Europe and parts of Asia. The problem for the CHC industry has always been that the benefits given to US companies gaining switch status – the cost to the patient-as-consumer drops substantially and there is often three years marketing exclusivity, whereas the ingredient can no longer be prescribed for the same indication – are not available to marketers in the rest of the world. That leads to the curious situation of some switches being regulatory wins but commercial failures. Let’s hope that Adamed is blessed with decent sales for its latest innovation.

Find solutions for success in this competitive CHC landscape with Nicholas and the team in Athens on 4-6 May 2022 for our 32nd European CHC Conference & Action Workshop! Meet with peers and hear from industry experts, including sessions from Bayer, Teva, J&J and many others face-to-face! For more information, or to reserve your seat, please contact elizabeth.bernos@NicholasHall.com.

Global CHC market +2.6% in MAT Q3 2021

The latest update from Nicholas Hall’s CHC database, DB6, shows that in MAT Q3 2021, the store retail CHC market advanced by 2.6%, a continued improvement over results seen throughout the year (vs -0.6% and +1.7% for MAT Q1 and Q2 respectively).

  • Vitamins, Minerals & Supplements (+6.1%) maintains its position as the fastest-growing category, albeit at a slightly slower rate. Stabilising immune-associated segments still contribute to a healthy topline performance as consumers continue to bolster natural defences; this, coupled with improvements in other subcategories (notably a return to growth for probiotics) has helped to keep the largest major category buoyant
  • Lifestyle CHC growth advanced to +5.9%, with eye care — the largest subcategory — returning a mid-single digit increase (+5.4%); this, alongside sustained double-digit increases in sedatives & sleep aids (+13.8%), as well as smaller categories such as emergency hormonal contraception and erectile dysfunction, boosted the topline
  • Gastrointestinals growth improved (+5.2%) with all subcategories once again seeing an upturn over the previous reporting period — a return to some “normalisation of life” (travel, dining out, etc.) has helped the wider category advance
  • Analgesics saw a further improvement overall (+3.6%) boosted by systemics returning to growth (+1.9%) after successive negative results, as well as consistent gains in topical formats (+7.2%)
  • Dermatologicals slowed further to +0.6% (vs +3.9% MAT Q2 21), a trend heavily impacted by the performance of antiseptics & disinfectants — the subcategory now declining by 9.8% following high growth levels seen in the peak of the pandemic
  • Cough, Cold & Allergy remains negative, with sales retracting by 5.3% in the 12 months to end-Sept 21. However, the macro trend continues to improve over the previous reporting periods (-14.5% and -9.7% for MAT Q1 and Q2 respectively) as incidence of typical seasonal pathologies rises vs a low comparator in 2020, with many players reporting improvements in quarterly terms

In terms of geographies:

  • Americas advanced by 2.4% (vs +1.3% MAT Q2 21) – N America now displaying a positive trend with continued improvements in USA & Canada. LatAm markets remain strong, with another double-digit result in Brazil (+12.1%), the most robust of the Top 20 markets
  • Asia held on to mid-level growth (+4.8%) in the reporting period; while the region continues to be impacted by loss of revenue from overseas visitors in key markets Japan (-2.1%) and Australia (-2.9%), steady single-digit increases in China and India helped to maintain the topline
  • Europe’s performance has flattened; Western European markets are improving (-2.0% vs -4.4% MAT Q2 21), impacted by the analgesics growth trend returning to positive, plus a softening decline for CCA over the previous reporting period. CEE markets advanced further, aided by mid-single-digit gains in Poland (+4.8%)

Nicholas Hall commented: Good news! My colleague Kayleigh Griffin-Hooper tells me that the latest DB6 data show that the store retail CHC market continued on a path to recovery in the 12 months to end-September. Broadly speaking, the majority of markets are returning to slightly stronger growth – or softer declines – compared to MAT Q2. Trends remain heavily influenced by the impact of Covid-19 across several healthcare segments – both positively and negatively – resulting in low level advances on a global level.

In three months’ time, when we have sales data for the Internet channel, it will be interesting to see whether this high-growth sector fully balances the softness in store retail sales.

We are pleased to announce that Nicholas Hall’s DB6 MAT Q3 2021 update is now available! Subscribers can access over 150,000 pieces of data, with more than 30,000 records covering 13,000+ brands and 3,000 companies across 63 countries. To find out more, or to set up a free demo, please contact kate.holdcroft@NicholasHall.com.

APAC E-Conference 2021 Awards

Commenting on our recent APAC e-Conference 2021, Nicholas Hall said: “This was a highly successful conference, with over 100 participants, but I can genuinely say that I hope it’s our last of this kind as I can’t wait to get back to face-to-face meetings next year in Athens, New Jersey and Singapore.”

  • The Nicholas Hall APAC Marketing Award 2021 was decided by delegates and The Winner was GSK’s “Panadol Take Care” campaign, which resulted in “record-breaking” market share and consumption growth. The campaign comprised two key elements: education on post-vaccination pain & fever and the role of Panadol in providing suitable and efficacious care for these symptoms. In addition to TV, promotion included traditional media channels; partnerships with Pandamart, Uber and Grab offering 30-60 minute delivery services for post-vaccination symptom management; social media activity; an online expert care portal; strong in-store visibility; a Take Care Chatbot; and out-of-home ads close to vaccination centres. 
  • 2nd place: Redoxon (Bayer) The “Ces Before Cus” campaign was implemented in Indonesia to help the vitamin fight back against increased competition during the pandemic and help consumers “be new normal ready” by boosting immunity and giving them more confidence when carrying out daily activities in the Covid era. “Ces” is the noise that Redoxon makes when dissolving in water and “cus” is Indonesian slang for “Let’s go!”
  • 3rd place: Eye-Mo (Combiphar) Following a return to the Singaporean market in 2017, it was noted that Millennials did not have a strong connection with the brand. Combiphar turned this around with the growth-driving “I See What I Want” campaign, fronted by teen singer Aden Tan, which aimed to empower the younger generation by helping them rebound from negativities and see “the brighter side of life”.

Review the full proceedings from our APAC e-Conference 2021 conference by purchasing a copy of the event recording. For more details, please contact elizabeth.bernos@NicholasHall.com.

Voice-activated tech shows potential for diabetes care

OTCINACTION

Diabetes affects 422mn people worldwide, including 14% of the US adult population and people in low and middle-income countries such as China, India, Brazil and Indonesia. To successfully manage diabetes, people living with it need to be mindful of and track myriad things throughout their day, from blood sugar levels to counting calories. In recent years voice-activated technologies have become an important way of helping sufferers manage their disease.

In this regard, Danish pharmaceutical company, Novo Nordisk, has teamed up with Health Innovation Technology Lab (HITLAB) to launch the 2017 HITLAB World Cup of Voice-Activated Technology in Diabetes, awarding prizes totalling US$75,000.

HITLAB_Novo-Nordisk-Voice-Activated-Technology-Diabetes

Participating innovators have been told to focus on enhancing patient outcomes, lowering healthcare costs and making the management of patients more efficient, with the goal of improving health and quality of life for diabetes sufferers.

Amy West, Senior Director, Patient Centric Marketing & Digital Health at Novo Nordisk commented: “We are constantly striving to provide solutions that minimise the burden for people living with diabetes, and believe that digital health, and specifically voice-activated technologies can be important tools for managing diabetes.”

heysiri-diabetes

HITLAB has helped leading organisations create and evaluate technology-based solutions to pressing healthcare challenges for the past 25 years. Last year, 74 teams from 14 countries presented technology innovations that ranged from a tech-enabled dynamic scoliosis brace to a tool that uses 3D imaging and data analytics to better diagnose ear infections. Past winners have since raised over US$50mn in follow-on investment funding.

The submission period is currently open and will close on Wednesday 11th October. Finalists will be announced on 23rd October. They will make pitches at the HITLAB Innovators Summit, which will be held in New York City. Pitches will be judged by a panel of healthcare experts assigned by Novo Nordisk and HITLAB.

App “as effective as the contraceptive pill”

A revolutionary form of contraception, especially available over-the-counter, has been long awaited. This year alone we have seen trials in male contraceptive injections and demands for numerous OTC contraceptive pills. Drastic change and action have long been in high demand.

What started out as a hobby project for Elina Berglund Scherwitzl has now become approved as the world’s first contraceptive app. The nuclear physicist, who had been working on the team that discovered the Higgs boson, felt finished with hormonal contraceptives and their physical and mental pitfalls, but was not yet ready to have a baby.

With a wealth of data skills, Elina was determined to find an alternative form of contraception. “Like many women I had tried many different contraception options since my teenage years and hadn’t really found a solution that fit me,” she explained. “It was in my quest for an effective natural alternative that I discovered that you can see when you’re fertile by your temperature, and for me that was really a revelation.”

Using complex mathematics and data analysis, Elina began developing an algorithm designed to be so accurate that it could identify exactly when in her cycle she would ovulate. This then enabled planning for when she would need to use protection, to a much higher degree of certainty than natural planning methods, which many women with timely periods are able to use.

These results proved to be so accurate that, together with her husband, fellow physicist, Raoul Scherwitzl, Elina set about founding her own business, Natural Cycles.

natural-cycles-contraception-app-2017-02-09-01.JPG

Natural Cycles is an app designed to help women around the world with their fertility and contraception needs, allowing them to collect their own temperature datasets and closely monitor their cycle trends in the process.

Launched in 2014, the app now has some 300,000 users, who pay a monthly or annual fee for the service. Following several medical trials, the app became the first tech-based device on the planet to be formally certified for use as contraception, in February this year. It gained approval for use across the EU after getting the green light from the German inspection and certification organisation Tuv Sud.

The start-up now markets itself as being “as effective as the pill” following one of the largest clinical studies in contraception involving more than 4,000 women, published in the peer-reviewed European Journal of Contraception and Reproductive Health Care.

The researchers, which included the co-founding couple, found that 7% of women who used the app in a “typical” way (allowing for some human error) got pregnant, compared to 9% taking the pill and less than 1% using IUD coils. “Just like the pill we need some effort from the user on a daily basis. But we really hope to be the default alternative if you don’t want to use hormonal contraception or IUDs,” Elina commented.

While the product is only currently certified in the EU, where its users are concentrated in the UK and the Nordics, it is available worldwide and, despite its earlier controversies, has attracted users in some 160 countries.

Are wearables wearing thin?

OTCinActionheader

The wearables market has had a rollercoaster ride in recent months. This time a year ago analysts were penning multi-billion dollar forecasts for the developers of health trackers and smartwatches. Apple was setting the stakes high, brazenly selling a gold edition of the Apple Watch for US$10,000.

More recently though, once popular fitness tracker brand, Jawbone, confirmed to TechCrunch that it would be leaving the consumer market in order to focus on healthcare providers. Microsoft have also removed its Fitness Band from its online store (although it is still available on Amazon); most significantly they will no longer provide the Band developer kits.

Fitbit remains a leading brand name, and is still very much the heart of the fitness tracker revolution. Fitbit recently acquired one of its rivals, Pebble Watch. However, on the downside, it was reported that the company were making staff cuts and founder James Park said the firm had experienced “softer than expected” sales during the 2016 Christmas period.

wearables-e1455299947895.jpg

Numerous devices claim to measure heart rate, sleep activity and count calories. Counting steps is seemingly the most common use for wearable devices, which has been edifying for many in terms of daily exercise expectations. Recently, though, experts have questioned whether the golden goal of walking 10,000 steps a day is actually worthwhile, and a US study concluded that health trackers did not aid weight loss.

Mr Bryant from Futuresource says many wearables aren’t yet independent enough and rely on being tethered to a smartphone, or replicate functionality, such as step counting, that the handset already has. However, Mr Bryant believes that while wearables may be down, they are not yet out.

“We feel the slowdown is temporary and the market will accelerate this year,” he said. He thinks that improved power, appearance, and mobile pay options could give them a boost alongside a maturing user group.

Wearable Devices will be one of many themes explored at our 28th Annual OTC INSIGHT European Conference & Action Workshop, being held in Munich in just over a month! The wider conference will focus on the theme of Making the Most of New Technology. To reserve one of our final few places, please contact lianne.hill@NicholasHall.com

New advice says eat 10 fruit & veg per day

OTCinActionheader

A study by Imperial College London has suggested we should eat 10 portions of fruit & vegetables a day. The study said that such eating habits could prevent 7.8 million premature deaths each year. The study also identified particular fruit & vegetables that reduced the risk of cancer and heart disease.

A portion counts as 80g (3oz) of fruit or vegetables, which is equal to a small banana, a pear, or three heaped tablespoons of spinach or peas. The findings were based on pooled data on 95 separate studies, involving the eating habits of two million people.

Lower risk of cancer was linked to eating green vegetables such as spinach and kale, yellow vegetables and cauliflower. Lower risk of heart disease and strokes was linked to eating apples, pears, citrus fruits and leafy greens.

The results, published in the International Journal of Epidemiology, also assessed the risk of dying before your time. Compared with eating no fruit or veg a day, it showed:

  • 200g cut the risk of cardiovascular disease by 13% while 800g cut the risk by 28%
  • 200g cut the risk of cancer by 4%, while 800g cut the risk by 13%
  • 200g cut the risk of a premature death by 15%, while 800g cut the risk by 31%

Fresh fruit stand with boysenberries, raspberries, cherries and grapes

The researchers do not know if eating even more fruit & vegetables than the newly suggested 10 portions would have even greater health benefits, as there is little evidence out there to review.

Dr Dagfinn Aune, one of the researchers, said: “Fruit & vegetables have been shown to reduce cholesterol levels, blood pressure and to boost the health of our blood vessels and immune system.” He continued: “This may be due to the complex network of nutrients they hold, including many antioxidants, which may reduce DNA damage and lead to a reduction in cancer risk.”

However the study also said that the benefits of this would be hard to integrate as many people struggle to even eat the five a day (400g) which is recommended by the World Health Organization. In the UK, only about one in three people eat this recommended portion, showing the huge potential for VMS marketers in terms of targeting their supplements at people that don’t eat their 10 fruit & veg a day.

Wearable Sensor Device Helps Visually Impaired Sense Environment

OTCinActionheader

VTT TecVTT Technical Research Centre of Finland has developed a wearable assistive device for the visually impaired, which enables them to sense their environment and move around more safely. The device, which is worn like a heart rate monitor, has been clinically tested.

The device functions on the basis of a radar system developed by VTT. The radar sends information to the user in the form of vibrations or voice feedback. It senses a majority of obstacles in the user’s surroundings, however difficulties do however remain in sensing objects such as thin branches and bushes.

“The novel aspect lies in a wearable sensor device which functions based on radio waves, so the signal is able to pass through clothing. This means that it can be worn discreetly under a coat, for example,” says Tero Kiuru, a Senior Scientist at VTT.

wearablesens

The radar has already been clinically tested in device trials approved by the National Supervisory Authority for Welfare and Health (Valvira), in which VTT’s partners were Kuopio University Hospital and the Finnish Federation of the Visually Impaired (FFVI). The test group included a total of 25 visually impaired people, of whom 14 were blind, 7 partially sighted and 4 were deaf-blind.

“A clear majority of the testers felt that the radar improved their ability to perceive their environment and increased their self-confidence when moving around,” says Kiuru. A total of 92% of the trial users felt that the device helped them to perceive their surroundings, 80% felt that their trust in their ability to move around independently had increased and 32% would immediately start using the test device in its current form.

On the other hand, they were not satisfied with distance control and vibration-based feedback. The research will continue with selected test users and the device will be further developed. A global market is believed to exist for the radar, since there are around 300 million visually impaired people in the world.